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 Abstract 
Aims: Catestatin (CST) limits myocardial ischaemia/reperfusion (I/R) injury with unknown 
mechanisms. Clearly phosphoinositide-3-kinase (PI3K), protein-kinase-C (PKC) isoforms, including 
intra-mitochondrial PKCε, mitochondrial-KATP (mitoKATP) channels and subsequent reactive-
oxygen-species (ROS)-signalling play important roles in postconditioning cardioprotection, 
preventing mitochondrial permeability transition pore (mPTP) opening. Therefore, we studied the 
role of these extra- and intra-mitochondrial factors in CST-induced protection. Methods and 
Results: Isolated rat hearts and H9c2 cells underwent I/R and oxidative stress, respectively. In 
isolated hearts CST (75nM, CST-Post) given in early-reperfusion significantly reduced infarct-size, 
limited post-ischaemic contracture, and improved recovery of developed left ventricular pressure. 
PI3K inhibitor, LY-294002 (LY), large spectrum PKC inhibitor, Chelerythrine (CHE), specific PKCε 
inhibitor (εV1-2), mitoKATP channel blocker, 5-Hydroxydecanoate (5HD) or ROS scavenger, 2-
mercaptopropionylglycine (MPG) abolished the infarct-sparing effect of CST. Notably the CST-
induced contracture limitation was maintained during co-infusion of 5HD, MPG or εV1-2, but it 
was lost during co-infusion of LY or CHE. In H9c2 cells challenged with H2O2, mitochondrial-
depolarization (an index of mPTP-opening studied with JC1-probe) was drastically limited by CST 
(75nM). Conclusions: Our results suggest that the protective signalling pathway activated by CST 
includes mitoKATP channels, ROS-signalling and prevention of mPTP opening, with a central role 
for upstream PI3K/Akt and PKCs. In fact, all inhibitors completely abolished CST-infarct-sparing 
effect. Since CST-anti-contracture effect cannot be explained by intra-mitochondrial mechanisms 
(PKCε activation and mitoKATP channel opening) or ROS-signalling, it is proposed that these 
downstream signals are part of a reverberant loop which re-activates upstream PKCs, which 
therefore play a pivotal role in CST-induced protection. 
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1. Introduction 
Rapid reperfusion is the gold-standard therapy for acute myocardial infarction (AMI). 
However reperfusion induces myocardial damages, which can be prevented by timing 
treatments in early reperfusion phase [7,13,21,34,53]. Reperfusion injury includes all 
forms of cell death as well as contractile dysfunction of surviving cells [7,13,34,53]. It has 
been shown that several peptides are able to induce cardioprotection when infused in the 
early reperfusion; that is pharmacological postconditioning [13,21,38,39]. These peptides, 
acting on their specific receptors, can trigger both pharmacological pre- and 
postconditioning via pro-survival intrinsic signalling pathways, which include in rodents 
the so called Reperfusion Injury Salvage Kinase (RISK) and Survivor Activating Factor 
Enhancement (SAFE) pathways [18,48]. 
Survival kinases, such as phosphatidylinositol-3-kinase (PI3K)/protein kinase B 
(Akt/PKB) and protein kinase C (PKC) may act on downstream mitochondrial targets to 
open ATP sensitive potassium (mitoKATP) channels and to affect cellular survival, 
reducing both necrosis and apoptosis [7,13,41,56]. The mitoKATP channels via multiple 
mechanisms, including the partial depolarization of the mitochondrial membrane, may 
favour reactive oxygen species (ROS)-signalling, which may lead to a re-activation of a 
pool of PKCs [15,35,53]. In particular, in concert with mitoKATP channels, the 
intramitochondrial protein kinase Cε (PKCε) activation may take part to the so-called 
“memory-associated protection”. Nevertheless, the signal transduction pathways for 
protection from lethal and non-lethal reperfusion injury are still under intense debate 
[2,7,9,15,18,34]. 
Recently, several biologically active peptides derived from chromogranin A (CgA), 
including Vasostatin-1 (VS-1) and Catestatin (CST), have received attention as regulators 
of cardiovascular function [2,11,12,19,22,29,43]. For instance, the N-terminal VS-1 
induced a preconditioning-like effect via adenosine/nitric oxide (NO) protective signalling, 
reducing the extension of myocardial infarction in the rat heart [10].  
The C-terminal CgA-derived peptide CST is a non-competitive antagonist of nicotine-
evoked catecholamine secretion [17,29,32] and it induces vasodilatation through both 
inhibition of catecholamine release and increased circulating levels of histamine [22,23]. 
CST plasma levels are decreased not only in hypertensive patients but also in their still-
normotensive offspring [27-29,32]; accordingly, exogenous CST rescues arterial 
hypertension of CgA knockout mice [28]. CST also caused vasodilatation in human 
subjects with a NO-dependent mechanism [16]. Recently, on the isolated rat heart, CST 
was found to elicit a vasorelaxant influence on coronary arteries pre-contracted by 
endothelin-1, together with negative inotropic and lusitropic actions, counteracting the 
positive effects elicited by the β-adrenoceptor activator, isoproterenol [3]. CST inhibition 
of β-adrenoceptor activation in cardiomyocytes [3] is “presumably mediated by the 
relaxing effect of the endothelial cell-derived NO-release mediated by Akt/PKB signalling 
to endothelial NO synthase” [19]. Importantly, in AMI patients an initial reduction with a 
subsequent increase in CST plasma levels has been recently reported [55]. 
We have studied the cardioprotective effect of CST infused during the early reperfusion as 
pharmacological postconditioning (CST-Post) [36]. CST-Post reduced post-ischaemic myocardial 
contracture and significantly improved post-ischaemic recovery of contractility. Using isolated 
cardiac cells, we also reported that the protection observed is primarily due to a direct effect on 
the cardiomyocytes and does not necessarily depend on the endothelial effects of CST [36]. Since 
in multiple models [39,41,42,51,52,56], including isolated cells [48,51,56], an involvement of 
PI3K/Akt, PKCs, mitoKATP channel and ROS-signalling have been observed in ischaemic 
postconditioning, we hypothesized that the CST-induced cardioprotective response in reperfusion 
may involve potential signalling proteins (e.g. PI3K/Akt and PKCs) and potential downstream 
targets and mediators (e.g. PKCε and mitoKATP channel activation, and ROS production). To 
explore the role of these elements in the CST-Post-induced cardioprotection, we used 
Langendorff rat hearts reperfused in the presence of inhibitors of either PI3K/Akt, PKCs, PKCε or 
mitoKATP channels or a ROS scavenger. Moreover, to corroborate the involvement of 
mitochondria in the CST-induced cardioprotection, we also studied CST protective role in cardiac 
cell line in the presence of oxidative stress, using a specific probe for the evaluation of intra-
mitochondrial potential variation. 
2. Methods 
2.1 Animals 
Male Wistar rats were used in accordance with the Italian law (DL-116, Jan. 27, 1992) and the 
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 
Health (NIH Publication No. 85-23, revised 1996). The project was approved by the Italian 
Ministry of Health, Rome, and by the ethics review board of the University of Turin. Adult rats 
were anaesthetized by i.p. injection of urethane (1 g/kg) and killed by decapitation. 
2.2 Isolated heart perfusion 
The methods were similar to those previously described [1,33,35,36,39-41]. In brief, after 
anaesthesia chest was opened and heart excised. Hearts were immediately constant-flow 
perfused with Krebs–Henseleit buffer solution (127 mM NaCl, 17.7 mM NaHCO3, 5.1 mM KCl, 1.5 
mM CaCl2, 1.26 mM MgCl2, 11 mM D-glucose (Sigma-Aldrich Corp., St. Louis, MO, USA) gassed 
with 95% O2 and 5% CO2. The hearts were instrumented to record coronary pressure and left 
ventricular pressure (LVP), electrically paced at 280 b.p.m. and kept in a temperature-controlled 
chamber (37°C) [1, 33,35,36,39-41]. 
2.2.1 Cardiac function and Infarct-size studies  
After 40 min stabilization, hearts were subjected to 30-min, normothermic, zero-flow global 
ischaemia, followed by 120-min reperfusion (Group 1, I/R).  
In a second Group (CST-Post group), CST (75nM) [36] was infused for 20-min at the beginning of 
reperfusion. Then the action of CST-Post was studied in the presence of specific inhibitors. 
In Group 3 and 4, the large spectrum PKC inhibitor, chelerythrine (CHE, 5μM; CST-Post+CHE 
Group) or the selective inhibitor of PI3K/Akt, LY-294002 (LY, 50μM; CST-Post+LY Group) were 
used to test the involvement of these pivotal kinases in cardioprotection scenario [35,42]. 
In Group 5 a specific PKCε inhibitor, εV1-2, was used to test the involvement of this kinase (εV1-2 
1μM; CST-Post+εV1-2 Group) [44]. 
In Group 6, the mitoKATP channel blocker, 5-hydroxydecanoate (5HD, 100μM; CST-Post+5HD 
Group) [41 and references therein] was used to test whether the action of CST-Post could include 
mitoKATP channel activation. 
In Group 7, to confirm ROS involvement, we used a ROS scavenger, 2-mercaptopropionylglycine 
(MPG, 300μM; CST-Post+MPG Group) which is a sulfhydryl donor specific for mitochondrial 
activity [30,39 and references therein]. 
Perfusion with inhibitors started 5-min before ischaemia and continued during the early 20-min 
of reperfusion in the presence of CST-Post (n= 8 for each group). The concentrations of inhibitors 
were chosen on the basis of data found in the literature [14,35,39,41-44 and references therein]. 
In preliminary experiments these doses of inhibitors did not affect basal cardiac performance. CST 
concentration was chosen on the basis of dose-response curve on infarct-size limitation [36]. 
2.2.2 Additional experiments 
To determine the effects of the antagonists themselves, control hearts were infused 5-min before 
the global ischaemia and during the initial 20-min of reperfusion with one only of the antagonists 
(CHE, LY, εV1-2, 5HD or MPG, Groups 8-12, n= 6 for each group).  
Moreover, in order to evaluate the effective role of CST in cardioprotection, in additional 
experiments, hearts were perfused with heat-inactivated CST [3] at the identical concentration of 
active CST (75nM), for 20-min at the beginning of reperfusion. 
At the end of the experiments all the hearts were removed from the apparatus to evaluate the 
extension of infarct-size.  
2.3 Assessment of cardiac function  
A polyvinyl-chloride balloon was placed into the left ventricle (LV) and connected to the 
electromanometer filled with saline to obtain an end diastolic LVP of 5 mmHg. Such a volume of 
LV was maintained throughout the experiment [33,35,36,39-41].  
Coronary perfusion pressure and LVP were monitored to assess the preparation conditions. LVP 
was analyzed offline with LabView software (National Instruments). Care was taken to measure 
LVP in a period (15–20 s) without arrhythmias. 
2.4 Assessment of myocardial injury 
Infarct areas were assessed at the end of the experiment as previously described [32,34,35,38-
40]. In brief, immediately after reperfusion hearts were rapidly removed from the perfusion 
apparatus and the LV dissected into 2–3 mm circumferential slices. Following 20 min of 
incubation at 37°C in 0.1% solution of nitro-blue tetrazolium in phosphate buffer, unstained 
necrotic tissue was carefully separated from stained viable tissue by an independent observer, 
who was unaware of the protocols. The necrotic mass was expressed as a percentage of total left 
ventricular mass. In fact, only the LV had a fixed volume and pre-load; therefore only the LV mass 
was considered as risk area, though in this model the whole heart underwent normothermic 
ischaemia. 
2.5 Oxidative stress and mitochondrial potential in H9c2 
2.5.1 Cell culture and drug treatment. 
The cardiac myoblast H9C2 cell line (ATCC, CRL-1446) was maintained in DMEM supplemented 
with 15% heat-inactivated FCS, 100 U/mL penicillin and 100 μg/mL streptomycin sulphate in a 
humidified incubator at 37ºC under 5% CO2/air prior to use. H9c2 cells were seeded in 
quadruplicate in 24-well plates and the experimental groups were: i) control: CTRL, absence of 
any additional treatment; ii) H2O2: H9c2 were exposed to 50µM H2O2 for 2 hours [20]; iii) CST: 
cells were exposed to CST 75nM for 3 hours; iv) CST+H2O2: cells were exposed to CST for 1 hour, 
then CST plus H2O2 were continued for other 2 hours. 
2.5.2 Cell survival 
The cell viability was determined by a colorimetric MTT assay, as described previously [54]. 
2.5.3 Measurement of mitochondrial potential  
The quantification of mitochondrial potential variation was obtained with JC-1 during fluorimetric 
analysis [45]. In brief, JC-1 (10µM) was added to cultured cells [46] in control and after the 
treatment with H2O2 (50µM) [20] with or without CST (75 nM). The ratio between red and green 
JC-1 florescence was taken as an index of mitochondrial membrane potential [25]. 
2.6 Drugs 
CST was a generous gift of Dr. Sushil K. Mahata (University of California and Veterans Affairs San 
Diego Healthcare System, San Diego, California; USA). CHE, MPG, LY, and 5HD were purchased 
from Sigma (St. Louis, MO, USA); εV1-2 from AnaSpec Inc. (Fremont, California, USA). 
2.7 Statistical analysis 
All data are expressed as means±SEM. One-way ANOVA and Newman–Keuls multiple comparison 
tests (for post-ANOVA comparisons) have been used to compare infarct-size. Functional data 
were compared with repeated measures ANOVA (time/group). A t test with Bonferroni correction 
was also used to compare the last-time points of functional data. Differences with p<0.05 were 
regarded as statistically significant. 
3. Results 
The baseline values of the considered parameters at the end of stabilization period were in the 
range of those usually used in this model. Specifically, a coronary perfusion pressure (CPP) of 
about 80 mmHg was obtained adjusting the coronary flow (CF) to 9±1 ml/min/g, and an end-
diastolic LVP (LVEDP) of about 5 mmHg was achieved adjusting the volume of the balloon placed 
into the LV. Basal values of CPP and LVEDP did not change significantly throughout the 
stabilization period. At the end of stabilization, the hearts developed a LVP (dLVP) of about 80 
mmHg. 
3.1 CST-Post improved post-ischaemic cardiac function in a PI3K/Akt and PKCs 
dependent manner 
3.1.1 Systolic function 
In Fig 1, panel A, developed LVP data are reported as percent variation with respect to baseline 
level. In Fig 1, panel B, dLVP data are reported as area under the curve (AUC) during reperfusion. 
The hearts of the I/R group showed a marked limitation of dLVP recovery during reperfusion; in 
fact, dLVP was 34±10% of baseline level at the end of reperfusion (dLVP decreased from 81±4 to 
28±6 mmHg; p<0.001, this p value is not reported in Fig 1A). 
As can be seen in Fig 1A and 1B, CST-Post markedly improved the dLVP recovery during 
reperfusion (p<0.01 vs. I/R group); in particular, at the end of reperfusion dLVP was 111±13% of 
baseline levels. The co-infusion of antagonists of upstream signals, such as LY or CHE (inhibitors of 
PI3K/Akt and PKCs, respectively), along with CST abolished the cardioprotective effects of CST-
Post (Fig 1A and 1B). However, the co-infusion of CST with antagonists of downstream signals, 
such as εV1-2, 5HD or MPG (inhibitors of PKCε,  mitoKATP channels or ROS scavenger, 
respectively), partially reduced the protective effect of CST-Post. Statistical analysis yielded 
similar results whether are compared the last time points (120
th
 min of reperfusion, Fig 1A) or the 
AUC (Fig 1B). 
3.1.2 Diastolic function 
In Fig 1, panel C, the levels of LVEDP are reported in mmHg throughout the entire experiment 
duration. In Fig 1, panel D, these data are reported as area under the curve (AUC) during 
reperfusion. Contracture can be defined as an increase in LVEDP of 4 mmHg above the baseline 
level [5,33]. 
I/R induced a marked increase of LVEDP, which reached 54±14 mmHg at the end of reperfusion 
(p<0.001 vs. baseline level; this p value is not reported in Fig 1). CST-Post significantly limited the 
development of contracture occurring during reperfusion; at the end of reperfusion, in fact, 
LVEDP was 23±7 mmHg (p<0.01 vs. I/R). Co-infusion with upstream antagonists (CHE or LY) 
abolished the protective effect of CST against contracture (p = NS vs. I/R last time point, Fig 1C). 
However, in the presence of these inhibitors (LY or CHE) the contracture development was 
somewhat slower than in I/R; in fact AUCs were smaller than I/R, though bigger than CST-Post (Fig 
1D). 
Yet the co-infusion with either εV1-2, 5HD or MPG (downstream antagonists) did not abolish the 
contracture limitation induced by CST-Post (p<0.01 vs. I/R last time point; p = NS vs. CST-Post last 
time point, Fig 1C). Similar results were shown by analysis of AUCs (Fig 1D). 
The cardiac function parameters observed in hearts perfused with only inhibitors (groups 
8-12) or inactivated-CST during reperfusion were similar to those observed in I/R group 
(data not shown). 
3.2 CST-Post limited infarct-size through PKC and mitoKATP channel involvement 
The risk area, i.e., left ventricular mass, was similar in all groups. Infarct-size (Fig 2A), 
expressed as a percentage of LV mass, was 67±6% in I/R. CST-Post reduced infarct-size 
to 37±4% of LV mass (p<0.01 vs. I/R). The co-infusion with either the upstream blockers 
(CHE or LY), or the downstream antagonists (εV1-2, 5HD or MPG) abolished the 
protective effect of CST against infarct size (see Fig. 2A). 
Risk area and infarct-size assessed in hearts perfused with only inhibitors (groups 8-12) 
were similar to those observed in I/R control group (Fig.2B). This lack of effects on I/R 
injury has been already reported [14,35,39,41-44]. 
The infusion of inactivated CST had no protective effects against infarct size (64±4%, p= 
NS vs. I/R, p<0.01 vs. CST-Post). 
3.3 CST protected the cultured cells from oxidative stress 
Figure 3 shows the protective effects of CST against oxidative stress in the H9c2 cells. 
Oxidative stress with H2O2 significantly reduced the survival of H9c2 cell (p<0.05 vs. 
Control group), and the co-treatment with CST abolished this effect (Fig 3A). 
3.3.1 CST avoided mitochondrial membrane potential dissipation due to oxidative stress 
As expected, H2O2 drastically reduced the mitochondrial potential (p<0.01 vs. CTLR and 
CST groups), while the co-treatment (CST+H2O2) significantly limited this reduction 
(p<0.05 vs. H2O2 and CTLR groups) (Fig 3B). Of note, CST per se induced a partial, non-
significant, depolarization of the mitochondrial membrane. 
 
4. Discussion  
The C-terminal fragment of Chromogranin A, CST, is known as an inhibitor of catecholamine 
secretion and a regulator of cardiovascular functions [19,23,28]. The cardiac activity of CST is 
achieved through signalling pathways expected for receptor-orphan peptides with membrane-
interacting properties [4]. Here, using classic antagonists [14,35,39,41-44], we demonstrated for 
the first time that the cardioprotective effect of CST-Post depends on the activation of PI3k/Akt, 
PKCs and of mitoKATP channels, which may include a ROS signalling. The prevention of mPTP 
opening in myocytes challenged with oxidative stress reinforces the idea that CST protective 
effects converge on mitochondria. 
Most studies with cardioprotective agents have addressed either the post-ischaemic mechanical 
recovery or the reduction of the infarct-size. Thus it remains unclear whether the mechanical 
recovery is attributable to the reduction of infarct-size only and/or to a direct effect of the 
cardioprotective agent on post-ischaemic mechanical function of myocardium. Here, we show 
that CST-Post significantly reduces both the extension of infarct-size and the myocardial 
contracture development drastically improving post-ischaemic systolic function during 
reperfusion (see Fig 1). Importantly, the distinct inhibitors targeting different elements of the 
protective pathway allow dissecting the effect on mechanical function and cell death. In fact, in 
the present study, all the antagonists used abrogate CST-Post protection against infarct-size 
development (Fig 2). However, the post-ischaemic contractile function was differently affected by 
antagonists of upstream and downstream targets of CST in the protective signalling pathway (Fig 
1 and Fig 4). 
CST-cardioprotective effects against infarct size were abolished by either upstream antagonists, 
namely the broad range inhibitor of PKCs, CHE, or the PI3K/Akt antagonist, LY, as well as by the 
downstream target antagonists, namely the specific PKCε antagonist, εV1-2, the mitoKATP channel 
blocker, 5HD, or the ROS scavenger, MPG. This supports the viewpoint that the activation of 
pathways both outside (PI3K/Akt and pool of PKCs) and inside the mitochondria (PKCε activation, 
mitoKATP channel opening and subsequent ROS diffusion) are required for CST-induced protection 
against infarct size. 
With respect to contracture development, we observed that its limitation by CST can only be 
slowed down in the presence of CHE and LY, but can be still reduced in the presence of the 
downstream target inhibitors (εV1-2, 5HD and MPG.) In other words, while CHE and LY were able 
to limit CST-induced contracture protection, εV1-2, 5HD or MPG (antagonists of mitochondrial 
factors) were not able to limit the protective effect of CST against contracture development. This 
suggests that the CST-induced limitation of contracture is mitochondrial-independent. Possible 
mechanisms include CST-induced phospholamban phosphorylation, as shown by Angelone et al 
[4]. 
It may be stressed that PKCε-dependent cardioprotection is mainly due to its mitochondrial 
activity. In fact, under I/R conditions mitochondrial translocation of PKCε occurs rapidly, with a 
corresponding decline in cytosolic PKCε levels [9]. Moreover, a number of cardioprotective stimuli 
enhance mitochondrial translocation of PKCε, which may mediate protection via the 
phosphorylation of intramitochondrial proteins [9 and references therein]. Therefore, it is not a 
surprise that the specific PKCε inhibitor, εV1-2, affects mitochondrial-dependent protection. 
Although several authors report that the ROS scavenger, MPG, given in reperfusion does not 
affect infarct size [13,14,26,34,39], it is currently unknown why the addition of MPG does not 
elicit any protection, but may limit cardioprotective efficacy of various protective interventions 
[13,14,26,34,39]. The most likely explanation is that the ROS signal is carried by specific radical 
species and/or in specific intracellular compartment [26,40]. MPG, which concentrates 500-fold in 
mitochondria and is highly effective against some mitochondrial ROS [26,30], evidently, is able to 
scavenge the few radical species that signal the protection, but is not effective against I/R injury 
due to massive ROS production [13,14,26,30,34,39]. 
We suggest that the activation of the PKCs pool is a pivotal step in CST-Post cardioprotection; in 
fact the co-infusion with CHE abolishes all CTS-Post-elicited protective effects (Figs 1 and 2). 
Likely, the mitoKATP channel opening with subsequent ROS formation signalling is implicated in the 
CST-Post induced protection [13,15,31]. In fact ROS can activate a redundant pool of kinases 
involved in cardioprotection [7,13,18,35,41], including PKCs, thus eliciting a positive feed-back 
loop [47], which may provide a sort of cardioprotection memory (reverberant loop, Fig 4) [15]. In 
fact εV1-2 and MPG, similarly to 5HD, only partially block the CST protective effects. Hence, we 
can argue that the above described memory effect is necessary for limiting the infarct, but less 
important for post-ischaemic contracture limitation. In fact, contracture limitation persists in εV1-
2, 5HD or MPG treated hearts. ROS, likely produced after mitoKATP channels opening, may act as 
double edge swords; that is, they may act as second messengers to trigger the pathway of 
protective kinases, being at the same time involved in mediating part of myocardial dysfunction 
[7,34,38].  
While the PKCs pool plays a pivotal role in the protective effects (see for instance the 
cardioprotective effect of the large spectrum PKC activator, 4 beta-phorbol 12-myristate 13-
acetate (PMA) [26], and our data with the large spectrum PKC inhibitor, CHE), the PKCε iso-
enzyme is only part of the reverberant loop. In fact, as said, the specific PKCε inhibitor, εV1-2, 
does not counteract the CST-induced contracture limitation. 
Theoretically, the improved systolic function might be due to the limitation of infarct-size and 
contracture, as well as to a direct CST induced anti-stunning effect. However, the long-lasting 
post-ischaemic systolic recovery in CST-Post experiments could not be explained by the inotropic 
effect of CST, which is known to exert transient (a few minutes) positive [6] and prolonged 
negative inotropic effects in normoxia [4,6]. Therefore, the CST-induced improvement of post-
ischaemic systolic function can be attributed to both the limitation of infarct-size and the 
prevention of contracture [36]. 
CST exerted direct protective effect against simulated I/R in isolated adult cardiomyocytes [36]. 
Of note, here, we show CST-protection on myocardial cell line, in which CST may induce a partial 
mitochondrial depolarization. Since the latter is considered part of the protective response of the 
targeted mitochondria [15,35,53], it is intriguing that CST may protect these cells against 
oxidative injury and excessive mitochondrial depolarization (Fig 3). Nevertheless, a cross-talk 
between endothelium and myocardium may play a role in the peptide induced protection [40], 
since the CST inotropic and anti-adrenergic effects have been attributed to a PI3K/Akt-dependent 
NO release from endothelial cells [4,6]. 
It has been reported that under certain conditions CST may exert deleterious effects and does not 
activate Akt [8]. Our results demonstrate that the CST-elicited cardioprotection is PI3K/Akt-
dependent, being abolished by the co-infusion of CST plus LY. It can be argued that the use of 
different models of ischaemia (e.g., global vs. regional ischaemia) and/or the dose/duration of 
treatment may be the cause of these conflicting results. In fact, depending on the conditions 
used, several substances may be protective or deleterious [13,35,37], as we and others have 
observed for other mediators such as platelet-activating factor [24,35,37] and Angeli’s salt, which 
are protective in pre- but not in postconditioning [32,33,37,38 and references therein]. 
In conclusion, our study demonstrates that CST-Post significantly reduces infarct-size and 
improves post-ischaemic cardiac function in isolated constant-flow perfused rat hearts; these 
effects being mediated via PI3K/Akt, PKCs and mitoKATP channel activation, thus favouring ROS 
signalling. By inhibiting alternatively PKCε only or various PKC isoforms, as well as signal elements 
of either upstream (PI3K/Akt) or downstream (mitoKATP channel opening and ROS formation) 
protective pathway, we have identified distinct components implicated in CST protection against 
infarct size and post-ischaemic contractile dysfunction. 
Clinical considerations 
The reported delayed increase of CST levels after infarction [55] may be implicated in the 
compensatory response against myocardial injury. Pharmacological postconditioning, which, 
however, target the first few minutes of reperfusion, may be clinically useful at the time of 
angioplasty, thrombolysis or cardiac surgery. 
Actually, CST is known to counteract exaggerated β-adrenergic activity, which is relevant part of 
the neuroendocrine scenario of heart failure [1-4], and to dilate human vessels in vivo [16], thus 
exerting positive effects on cardiac afterload. In line with these evidences and since β-blockade is 
largely used as post-ischaemic treatment, the present work suggests that exogenous CST may 
provide new tool for pharmacological postconditioning. 
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 Figure Legends 
Fig 1. Cardiac performance.  
A Percent variation of developed LVP (dLVP) during the 30-min ischaemia (delimited by two 
vertical dashed lines) and the 120-min reperfusion; data are presented as percent changes with 
respect to baseline level for each group.  
B Area under the curve (AUC): dLVP  recovery during the 120 min of reperfusion (a.u.: arbitrary 
units).  
C Left ventricular end-diastolic pressure (LVEDP) during the 30-min ischaemia (delimited by two 
vertical dashed lines) and the 120-min reperfusion; data are expressed in mmHg.  
D Area under the curve (AUC): LVEDP recovery during the 120 min of reperfusion (a.u.: arbitrary 
units). 
*p<0.01 vs. all groups; #p<0.05 vs. I/R and CST-Post-CHE; °p<0.05 vs. CST-Post; §p < 0.05; NS: not 
significant. 
 
Fig 2.  Infarct-size.  
The amount of necrotic tissue is expressed as percent of the left ventricle (% IS/LV), which is 
considered the risk area. A Effects of CST-Post with and without antagonists. B Effects of 
antagonists only (for comparative purpose are also reported I/R and CST-Post groups). 
**p<0.01 with respect to I/R; NS: not significant.  
 
Fig 3.  Oxidative stress and mitochondrial potential in H9c2. 
A Effects of H2O2 on the cell survival with and without CST; B Measurement of mitochondrial 
potential with JC-1 in H9c2 in the presence and in the absence of H2O2 with and without CST. Data 
presented are mean values±SEM of four experiments. 
*p<0.05 vs. all groups; **p<0.01 vs. all groups; #p<0.05 vs. Control and H2O2.  
 
Fig 4. Hypothetical scheme outlining the ‘reverberant’ pathway between PKCε and mitoKATP 
channels, at the time of reperfusion, in response to CST-Post.  
The hypothetical reverberant protective pathway may converge on the pivotal PKCs. This may 
explain why the inhibition of the main pathway using CHE, the inhibitor of PKCs, abolishes all the 
protective effects, whereas blockade of mitoKATP channels with 5HD and PKCε with εV1-2, as well 
as the ROS scavenger MPG can limit only part of the cardioprotective effects. For further 
explanations, see text. 
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